References
- 1. Brian I. Carr-Tumors of the liver and biliary tree, In: Dan L. Longo MD, Anthony S. Fauci MD, Harrison’s Gastroenterology and Hepatology, McGrawHill Education, United States, 2013:535-544.
- 2. EASL-EORTC- Clinical Practice Guidelines, Journal of Hepatology 2012;56:908-943.10.1016/j.jhep.2011.12.00122424438
- 3. National Cancer Institute. PDQ_ levels of evidence for adult and pediatric cancer treatment studies. Bethesda, MD: National Cancer Institute. Date last modified 26/August/2010.
- 4. Grieco A, Pompili, M, Caminiti, G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre., Gut, 2005; 54,3:411-418.10.1136/gut.2004.048124177442215710992
- 5. Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008;48:137-145.10.1002/hep.2231218537177
- 6. Yang HI, Sherman M, Su J, et al. Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. J Clin Oncol. 2010;28: 2437-2444.10.1200/JCO.2009.27.445620368541
- 7. Chen JD, Yang HI, Iloeje UH, et al. Carriers of Inactive Hepatitis B Virus Are Still at Risk forHepatocellular Carcinoma and Liver-Related Death. Gastroenterology 2010;135:1747-1754.10.1053/j.gastro.2010.01.04220114048
- 8. Dhir RN, Dworakowski W, Thangavel C, Shapiro BH. Sexually dimorphic regulation of hepatic isoforms of human cytochrome p450 by growth hormone. J Pharmacol Exp Ther 2006;316:87-94.10.1124/jpet.105.09377316160083
- 9. Waxman DJ, Holloway MG. Centennial perspective: sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009;76: 215-228.10.1124/mol.109.056705271311819483103
- 10. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:5(1):S5-S16.10.1053/j.gastro.2004.09.01115508102
- 11. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int. J. Cancer 2000;85: 498-502.
- 12. Amarapurkar D, Das HS. Chronic liver disease in diabetes mellitus. Tropical Gastroenterol 2002;23:3-5.
- 13. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468.10.1053/j.gastro.2003.10.06514762783
- 14. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124:71-79.10.1053/gast.2003.5000412512031
- 15. Zen Y, Katayanagi K, Tsuneyama K, et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001;51:127-131.10.1046/j.1440-1827.2001.01174.x11169153
- 16. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012;56:704-71310.1016/j.jhep.2011.09.020388966022120206
- 17. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-148.10.1053/j.gastro.2008.09.014374992218848939
- 18. Yang HI, Sherman M, Su J, et al. Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. J Clin Oncol 2010;28: 2437-2444.10.1200/JCO.2009.27.445620368541
- 19. Chen JD, Yang HI, Iloeje UH, et al. Carriers of Inactive Hepatitis B Virus Are Still at Risk forHepatocellular Carcinoma and Liver-Related Death. Gastroenterology 2010;135:1747-1754.10.1053/j.gastro.2010.01.04220114048